Low-cost treatment for multiple sclerosis shown to be as effective as standard therapy

AI Summary

A clinical trial conducted by Norwegian and Swedish researchers found that rituximab, a low-cost therapy, is as effective as the standard ocrelizumab treatment for newly diagnosed relapsing multiple sclerosis. The 30-month randomized double-blind study monitored patients across Norway and Sweden using MRI and clinical assessments.

A Norwegian-Swedish clinical trial published in the New England Journal of Medicine demonstrates that rituximab, a low-cost B-cell-depleting therapy, is as effective as ocrelizumab in newly diagnosed relapsing multiple sclerosis (MS). The study, known as OVERLORD-MS, is the first randomized, double-blind, head-to-head trial comparing the two therapies in early MS. Patients from across Norway and Sweden were followed for 30 months with MRI and clinical assessments.